Name | Value |
---|---|
Revenues | 271.1K |
Cost of Revenue | 312.4K |
Gross Profit | -41.3K |
Operating Expense | 3,421.4K |
Operating I/L | -3,462.6K |
Other Income/Expense | -136.9K |
Interest Income | 224.7K |
Pretax | -3,599.5K |
Income Tax Expense | -0.0K |
Net Income/Loss | -3,599.5K |
Femasys Inc. is a biomedical company specializing in women's healthcare solutions. The company's primary focus is on developing and commercializing a range of products for permanent birth control, artificial insemination, endocervical curettage, and uterine cancer detection testing. Their products, including FemBloc, FemChec, FemaSeed, FemCerv, and FemEMB, are targeted at obstetrics-gynecological physicians, reproductive endocrinologists, and women's healthcare provider organizations. Femasys also offers non-surgical product technologies to support their core offerings, generating revenue from sales in the United States, Europe, Canada, Japan, and other international markets.